

**FORM 51-102F3
MATERIAL CHANGE REPORT**

Item 1: Name and Address of Company

NurExone Biologic Inc. (the “Company” or “NurExone”)
1 Adelaide Street East, Suite 801
Toronto, Ontario M5C 2V9

Item 2: Dates of Material Changes

January 28, 2026 and January 30, 2026.

Item 3: News Releases

A news release was disseminated via Globe Newswire and filed on the Company’s SEDAR+ profile at www.sedarplus.ca on January 30, 2026.

Item 4: Summary of Material Change

Please see Item 5.1 below for a full description of the material changes.

Item 5.1: Full Description of Material Change

Effective January 28, 2026, Dr. Gadi Riesenfeld resigned from the board of directors of the Company (the “Board”). Effective January 30, 2026, Mr. Eyal Gabbai was appointed to the Board to fill the vacancy created by Dr. Riesenfeld’s resignation. Dr. Riesenfeld will continue to support NurExone as a member of the Company’s scientific advisory board.

Item 5.2: Disclosure for Restructuring Transactions

Not applicable.

Item 6: Reliance on Subsection 7.1(2) of National Instrument 51-102 (Confidentiality)

Not applicable.

Item 7: Omitted Information

No information has been omitted on the basis that it is confidential information.

Item 8: Executive Officer

For additional information with respect to this material change, please contact:

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Item 9: Date of Report

February 5, 2026.